UBS Group’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $44.9M | Buy |
1,380,853
+300,457
| +28% | +$9.77M | 0.01% | 1283 |
|
|
2025
Q1 | $40.8M | Buy |
1,080,396
+343,835
| +47% | +$13M | 0.01% | 1320 |
|
|
2024
Q4 | $60.3M | Buy |
736,561
+624,988
| +560% | +$51.2M | 0.01% | 1003 |
|
|
2024
Q3 | $12.7M | Buy |
111,573
+15,897
| +17% | +$1.82M | ﹤0.01% | 1525 |
|
|
2024
Q2 | $7.22M | Sell |
95,676
-80,402
| -46% | -$6.07M | ﹤0.01% | 1835 |
|
|
2024
Q1 | $12M | Buy |
176,078
+10,044
| +6% | +$686K | ﹤0.01% | 1495 |
|
|
2023
Q4 | $10.4M | Buy |
166,034
+91,729
| +123% | +$5.76M | ﹤0.01% | 1435 |
|
|
2023
Q3 | $3.79M | Buy |
74,305
+28,483
| +62% | +$1.45M | ﹤0.01% | 2066 |
|
|
2023
Q2 | $2.29M | Buy |
45,822
+45,478
| +13,220% | +$2.27M | ﹤0.01% | 2587 |
|
|
2023
Q1 | $12.9K | Sell |
344
-122,376
| -100% | -$4.59M | ﹤0.01% | 6332 |
|
|
2022
Q4 | $5.88M | Buy |
122,720
+122,645
| +163,527% | +$5.88M | ﹤0.01% | 1709 |
|
|
2022
Q3 | $2K | Sell |
75
-23,498
| -100% | -$627K | ﹤0.01% | 8650 |
|
|
2022
Q2 | $513K | Sell |
23,573
-36,814
| -61% | -$801K | ﹤0.01% | 3333 |
|
|
2022
Q1 | $1.46M | Buy |
60,387
+15,152
| +33% | +$366K | ﹤0.01% | 2922 |
|
|
2021
Q4 | $1.08M | Sell |
45,235
-76,552
| -63% | -$1.82M | ﹤0.01% | 3386 |
|
|
2021
Q3 | $3.09M | Buy |
121,787
+13,884
| +13% | +$352K | ﹤0.01% | 2421 |
|
|
2021
Q2 | $2.43M | Sell |
107,903
-7,547
| -7% | -$170K | ﹤0.01% | 2590 |
|
|
2021
Q1 | $2.28M | Buy |
115,450
+47,284
| +69% | +$934K | ﹤0.01% | 2652 |
|
|
2020
Q4 | $1.81M | Buy |
68,166
+67,446
| +9,368% | +$1.79M | ﹤0.01% | 2702 |
|
|
2020
Q3 | $36K | Buy |
+720
| New | +$36K | ﹤0.01% | 5011 |
|